205 related articles for article (PubMed ID: 31396371)
1. Positron emission tomography/computed tomography imaging appearance of benign and classic "do not touch" osseous lesions.
Elangovan SM; Sebro R
World J Radiol; 2019 Jun; 11(6):81-93. PubMed ID: 31396371
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
4. Role of ¹⁸F-FDG PET/CT in differentiation of a benign lesion and metastasis on the ribs of cancer patients.
Choi HS; Yoo IeR; Park HL; Choi EK; Kim SH; Lee WH
Clin Imaging; 2014; 38(2):109-14. PubMed ID: 24361174
[TBL] [Abstract][Full Text] [Related]
5. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
Choi JY; Lee KS; Kim HJ; Shim YM; Kwon OJ; Park K; Baek CH; Chung JH; Lee KH; Kim BT
J Nucl Med; 2006 Apr; 47(4):609-15. PubMed ID: 16595494
[TBL] [Abstract][Full Text] [Related]
6. Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors.
Huang YE; Chen CF; Huang YJ; Konda SD; Appelbaum DE; Pu Y
Acta Radiol; 2010 Sep; 51(7):782-8. PubMed ID: 20707663
[TBL] [Abstract][Full Text] [Related]
7. Dual time point 2-[18F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis.
Sahlmann CO; Siefker U; Lehmann K; Meller J
Nucl Med Commun; 2004 Aug; 25(8):819-23. PubMed ID: 15266177
[TBL] [Abstract][Full Text] [Related]
8. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
9. Dual time point fluorodeoxyglucose positron emission tomography/computed tomography in differentiation between malignant and benign lesions in cancer patients. Does it always work?
Saleh Farghaly HR; Mohamed Sayed MH; Nasr HA; Abdelaziz Maklad AM
Indian J Nucl Med; 2015; 30(4):314-9. PubMed ID: 26430314
[TBL] [Abstract][Full Text] [Related]
10. Utility of 18F-FDG PET/CT in the diagnosis and staging of extramammary Paget's disease.
Tian Y; Wu HB; Li DL; Li HS; Zhou WL; Wang QS
Nucl Med Commun; 2015 Sep; 36(9):892-7. PubMed ID: 25932540
[TBL] [Abstract][Full Text] [Related]
11. (18)F-FDG positron emission tomography/computed tomography and (99m)Tc-MDP skeletal scintigraphy in a case of Erdheim-Chester disease.
Asabella AN; Cimmino A; Altini C; Notaristefano A; Rubini G
Hell J Nucl Med; 2011; 14(3):311-2. PubMed ID: 22087457
[TBL] [Abstract][Full Text] [Related]
12. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of focal thyroid lesions incidentally detected in fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography images.
Yaylali O; Kirac FS; Yuksel D; Marangoz E
Indian J Cancer; 2014; 51(3):236-240. PubMed ID: 25494112
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of 18F-FDG-PET/CT in staging cutaneous squamous cell carcinoma.
Mahajan S; Barker CA; Singh B; Pandit-Taskar N
Nucl Med Commun; 2019 Jul; 40(7):744-751. PubMed ID: 31095044
[TBL] [Abstract][Full Text] [Related]
15. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
16. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
17.
Bosma SE; Vriens D; Gelderblom H; van de Sande MAJ; Dijkstra PDS; Bloem JL
Skeletal Radiol; 2019 Nov; 48(11):1735-1746. PubMed ID: 31016339
[TBL] [Abstract][Full Text] [Related]
18. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET-CT in the diagnosis of tumor thrombus: can it be differentiated from benign thrombus?
Sharma P; Kumar R; Jeph S; Karunanithi S; Naswa N; Gupta A; Malhotra A
Nucl Med Commun; 2011 Sep; 32(9):782-8. PubMed ID: 21799368
[TBL] [Abstract][Full Text] [Related]
20. Characterization of pulmonary lesions with low F-18 FDG uptake using double phase F-18 FDG PET/CT: comparison of visual and quantitative analyses.
Kim IJ; Kim SJ; Kim YS; Lee TH; Jeong YJ
Neoplasma; 2009; 56(1):33-9. PubMed ID: 19152243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
